[
  {
    "ts": null,
    "headline": "More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off.",
    "summary": "A triglyceride-cutting drug from  Ionis Pharmaceuticals  proved so effective in a trial reported this past weekend that the biotech’s shares jumped more than 30%.  Other news at the European Society of Cardiology Congress featured an  AstraZeneca  pill that the company thinks will become the best treatment for hard-to-control high blood pressure.  Merck offered a hint about a new cholesterol treatment, saying the long-awaited pill for lowering cholesterol achieved “meaningful” reductions in a Phase 3 trial.",
    "url": "https://finnhub.io/api/news?id=5bbb3bde79059b661fd16293170b24d210d814a41e6a015fef794889822003c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756854000,
      "headline": "More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off.",
      "id": 136612872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A triglyceride-cutting drug from  Ionis Pharmaceuticals  proved so effective in a trial reported this past weekend that the biotech’s shares jumped more than 30%.  Other news at the European Society of Cardiology Congress featured an  AstraZeneca  pill that the company thinks will become the best treatment for hard-to-control high blood pressure.  Merck offered a hint about a new cholesterol treatment, saying the long-awaited pill for lowering cholesterol achieved “meaningful” reductions in a Phase 3 trial.",
      "url": "https://finnhub.io/api/news?id=5bbb3bde79059b661fd16293170b24d210d814a41e6a015fef794889822003c2"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Recap: Alphabet, Nvidia, Comerica, Constellation Brands",
    "summary": "↗️Alphabet (GOOGL): The Google parent's stock rose 8% postmarket after a federal judge issued remedies in a monopoly case that were initially viewed as manageable for the search giant. Apple (AAPL) shares also advanced 3%.",
    "url": "https://finnhub.io/api/news?id=a252163d16f7b4eee573a937e6f44f3b05f91b8fe355da00647518dabb8a19d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756849748,
      "headline": "Stocks to Watch Recap: Alphabet, Nvidia, Comerica, Constellation Brands",
      "id": 136612873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️Alphabet (GOOGL): The Google parent's stock rose 8% postmarket after a federal judge issued remedies in a monopoly case that were initially viewed as manageable for the search giant. Apple (AAPL) shares also advanced 3%.",
      "url": "https://finnhub.io/api/news?id=a252163d16f7b4eee573a937e6f44f3b05f91b8fe355da00647518dabb8a19d1"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2025 Update",
    "summary": "Duquesne Family Office's Q2 2025 portfolio updates: key bets in tech & healthcare, new positions, and Druckenmiller's trend-driven investment strategy. See more.",
    "url": "https://finnhub.io/api/news?id=315d9f22e7d3c057f52bab7338e438e39f181b472233cbb7ba0439567411a854",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756849047,
      "headline": "Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2025 Update",
      "id": 136609890,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473159542/image_1473159542.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Duquesne Family Office's Q2 2025 portfolio updates: key bets in tech & healthcare, new positions, and Druckenmiller's trend-driven investment strategy. See more.",
      "url": "https://finnhub.io/api/news?id=315d9f22e7d3c057f52bab7338e438e39f181b472233cbb7ba0439567411a854"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=ad09a8413baa44cd27959f8443efc0ef480afeac7d01b47cbb5ff386a335eb85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756848333,
      "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136612874,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=ad09a8413baa44cd27959f8443efc0ef480afeac7d01b47cbb5ff386a335eb85"
    }
  },
  {
    "ts": null,
    "headline": "These 3 Companies are Seeing Supercharged Sales Growth",
    "summary": "The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.",
    "url": "https://finnhub.io/api/news?id=3c80d5c28410dcb362268d017d9cb0b9b2d7541dd8be7ad104aa68a0dd1f731c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756830600,
      "headline": "These 3 Companies are Seeing Supercharged Sales Growth",
      "id": 136612875,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.",
      "url": "https://finnhub.io/api/news?id=3c80d5c28410dcb362268d017d9cb0b9b2d7541dd8be7ad104aa68a0dd1f731c"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Affirms Eli Lilly (LLY)’s ‘Outperform’ Rating on Weight Loss Drug Prospects",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top stock picks in Ken Griffin’s portfolio. On August 27, BMO Capital reiterated its ‘Outperform’ rating with a $840 price target for the stock. The positive stance comes on the pharmaceutical giant delivering positive ATTAIN-2 clinical trial results for the weight loss drug orforglipron. The ATTAIN-2 […]",
    "url": "https://finnhub.io/api/news?id=b327f1fcc2d73fcf29f8df62de86f8b0ad19a39c73d22e786a9e1feec0bc0aab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756829615,
      "headline": "BMO Capital Affirms Eli Lilly (LLY)’s ‘Outperform’ Rating on Weight Loss Drug Prospects",
      "id": 136612876,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top stock picks in Ken Griffin’s portfolio. On August 27, BMO Capital reiterated its ‘Outperform’ rating with a $840 price target for the stock. The positive stance comes on the pharmaceutical giant delivering positive ATTAIN-2 clinical trial results for the weight loss drug orforglipron. The ATTAIN-2 […]",
      "url": "https://finnhub.io/api/news?id=b327f1fcc2d73fcf29f8df62de86f8b0ad19a39c73d22e786a9e1feec0bc0aab"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics Loses 20% in a Month: How to Play the Stock",
    "summary": "VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.",
    "url": "https://finnhub.io/api/news?id=a1d6c8ec25251abb7baee29c1d632c929dba68d6d7dbfea896e39c2003bf186b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756827000,
      "headline": "Viking Therapeutics Loses 20% in a Month: How to Play the Stock",
      "id": 136612877,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.",
      "url": "https://finnhub.io/api/news?id=a1d6c8ec25251abb7baee29c1d632c929dba68d6d7dbfea896e39c2003bf186b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales",
    "summary": "Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.",
    "url": "https://finnhub.io/api/news?id=f7b8a5b03937a6c38486617ec514d6c3f02ebf94ec57448fba034c5c55d8e281",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756825260,
      "headline": "Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales",
      "id": 136612878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.",
      "url": "https://finnhub.io/api/news?id=f7b8a5b03937a6c38486617ec514d6c3f02ebf94ec57448fba034c5c55d8e281"
    }
  },
  {
    "ts": null,
    "headline": "GSK Adds Around $5B in a Month: Here's How to Play the Stock",
    "summary": "GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.",
    "url": "https://finnhub.io/api/news?id=028f225eea9c5d7fa896c4f3e16e91ccb5b680bafe097de3c3114efaf0fae10c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756824480,
      "headline": "GSK Adds Around $5B in a Month: Here's How to Play the Stock",
      "id": 136612879,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.",
      "url": "https://finnhub.io/api/news?id=028f225eea9c5d7fa896c4f3e16e91ccb5b680bafe097de3c3114efaf0fae10c"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death",
    "summary": "Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with tirzepatide treatment in people with overweight or obesity and established cardiovascular disease (CVD) without diabetes. Compared with Eli Lilly and Co.’s (NYSE:LLY) tirze",
    "url": "https://finnhub.io/api/news?id=703285cd0de8b75aca5d866bb0bb490d1826725defffabfe2123eced67ad019e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756821947,
      "headline": "Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death",
      "id": 136612880,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with tirzepatide treatment in people with overweight or obesity and established cardiovascular disease (CVD) without diabetes. Compared with Eli Lilly and Co.’s (NYSE:LLY) tirze",
      "url": "https://finnhub.io/api/news?id=703285cd0de8b75aca5d866bb0bb490d1826725defffabfe2123eced67ad019e"
    }
  },
  {
    "ts": null,
    "headline": "Chinese companies turn to generics as shipments behind US weight-loss craze fade",
    "summary": "NEW YORK (Reuters) -Some Chinese companies now racing to make generic versions of Novo Nordisk's Wegovy also supplied ingredients for more than a billion makeshift doses of weight-loss drugs sold online in the U.S. over the past two years, according to three sources and a Reuters review of shipping and public records.  Cheap copies of Wegovy and Eli Lilly's Zepbound are on the retreat in the U.S. as regulators restrict their sale, slowing shipments from Chinese suppliers of the raw ingredients that allowed for explosive growth of the medicines.  Robert Califf, who had two stints leading the U.S. Food and Drug Administration, said never before had a new drug become so wildly popular that the manufacturer simply couldn’t keep up.",
    "url": "https://finnhub.io/api/news?id=29cc5f2a956196332b605e9ff93de1b672fb6230f743e32b51f0d12aa78ec278",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756811062,
      "headline": "Chinese companies turn to generics as shipments behind US weight-loss craze fade",
      "id": 136612881,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NEW YORK (Reuters) -Some Chinese companies now racing to make generic versions of Novo Nordisk's Wegovy also supplied ingredients for more than a billion makeshift doses of weight-loss drugs sold online in the U.S. over the past two years, according to three sources and a Reuters review of shipping and public records.  Cheap copies of Wegovy and Eli Lilly's Zepbound are on the retreat in the U.S. as regulators restrict their sale, slowing shipments from Chinese suppliers of the raw ingredients that allowed for explosive growth of the medicines.  Robert Califf, who had two stints leading the U.S. Food and Drug Administration, said never before had a new drug become so wildly popular that the manufacturer simply couldn’t keep up.",
      "url": "https://finnhub.io/api/news?id=29cc5f2a956196332b605e9ff93de1b672fb6230f743e32b51f0d12aa78ec278"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY)’s Oral Obesity Drug Orforglipron Achieves Breakthrough Phase 3 Results",
    "summary": "We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Eli Lilly and Company is one of them Eli Lilly and Company (NYSE:LLY) tops our list for being one of the best pharmaceutical stocks. It is a global pharmaceutical leader in diabetes, oncology, and neuroscience, and continues to […]",
    "url": "https://finnhub.io/api/news?id=35f8f40cac076fe88247e02d02433950e04775ad6907c0e43125e25ba843300b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756803794,
      "headline": "Eli Lilly and Company (LLY)’s Oral Obesity Drug Orforglipron Achieves Breakthrough Phase 3 Results",
      "id": 136604055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Eli Lilly and Company is one of them Eli Lilly and Company (NYSE:LLY) tops our list for being one of the best pharmaceutical stocks. It is a global pharmaceutical leader in diabetes, oncology, and neuroscience, and continues to […]",
      "url": "https://finnhub.io/api/news?id=35f8f40cac076fe88247e02d02433950e04775ad6907c0e43125e25ba843300b"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia Q2: The Irreplaceable AI Power You'll Regret Not Owning",
    "summary": "Nvidia Corporation's Q2 '26 results show 56% revenue growth and AI market dominance. Click for why experts rate NVDA a strong buy despite high valuation.",
    "url": "https://finnhub.io/api/news?id=9311ed71a56fa112fb1251313c3b32ace379c792c919d98eef77da356cd6e490",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756803157,
      "headline": "Nvidia Q2: The Irreplaceable AI Power You'll Regret Not Owning",
      "id": 136605820,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Nvidia Corporation's Q2 '26 results show 56% revenue growth and AI market dominance. Click for why experts rate NVDA a strong buy despite high valuation.",
      "url": "https://finnhub.io/api/news?id=9311ed71a56fa112fb1251313c3b32ace379c792c919d98eef77da356cd6e490"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Halts UK Mounjaro Shipments Ahead of Planned Price Increase",
    "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Eli Lilly and Company is one of them. Eli Lilly and Company (NYSE:LLY) tops our list for being one of the high growth stocks. It is a global pharmaceutical leader and continues to drive growth in 2025 through innovative […]",
    "url": "https://finnhub.io/api/news?id=be79bd15c570dcd1377f5c12a2781da9e66d7d6660208cc5348e8f965a017948",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756801601,
      "headline": "Eli Lilly and Company (LLY) Halts UK Mounjaro Shipments Ahead of Planned Price Increase",
      "id": 136604056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Eli Lilly and Company is one of them. Eli Lilly and Company (NYSE:LLY) tops our list for being one of the high growth stocks. It is a global pharmaceutical leader and continues to drive growth in 2025 through innovative […]",
      "url": "https://finnhub.io/api/news?id=be79bd15c570dcd1377f5c12a2781da9e66d7d6660208cc5348e8f965a017948"
    }
  }
]